Alteogen's SC technology value grows as Enhertu gets early breast cancer approval in Europe?
Predicted impact: Low
Enhertu approval and SC platform research already widely reported.
Alteogen알테오젠
196170 · KOSDAQ · ₩196170 · 알테오젠
₩218,500 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Daedeok special district launches bio deep-tech open innovation with Alteogen; recruiting collaborative technologies
Predicted impact: Low
Open innovation with Daedeok zone repeats an earlier joint development report; small and exploratory.
Alteogen to seek next-generation drug candidates, pursues joint development with Daeduck Special Zone
Predicted impact: Low
Research collaboration to seek drug candidates is early-stage with no disclosed financial size.
Next-generation anticancer drug delivered by subcutaneous injection… Alteogen presents research at European conference
Predicted impact: Low
Conference research presentation; similar subcutaneous research already reported recently.
Alteogen Presents Research on Subcutaneous ADC Formulation at European Cancer Congress
Predicted impact: Low
Research presentation on subcutaneous ADC formulation at a conference; early-stage, no deal size given
SK hynix, Lotte rental, Alteogen [Hana Securities weekly recommended stocks]
Predicted impact: Low
Broker weekly recommendation list; no new company-specific event beyond earlier reported news.
Alteogen-powered Keytruda SC expands bladder cancer indication in Europe
Predicted impact: Low
Keytruda SC indication expansion is a partner's approval news; no revenue size disclosed.
Alteogen earns Gold Medal in EcoVadis ESG rating; 'top 4% globally'
Predicted impact: Low
ESG rating award; routine recognition with no financial size.
Alteogen vs. Halozyme...Patent and Commercialization Race in the Subcutaneous Injection Market [Bio Platform War ②]
Predicted impact: Low
Feature article on patent and commercialization competition with Halozyme; no new event or figures.
Alteogen, which lost ₩3.2T in market cap over 6 days, jumps ₩1.4T in a single day
Predicted impact: Low
Securities issuance result disclosure and shareholder commentary; size not given in the item.
Alteogen shareholders weigh growth drivers as shares plunge; Park Soon-jae says new technology under review
Predicted impact: Medium· Actual: +2.2% vs sector, volume 1.0× normal (5 trading days)
Shares plunged and company reviewing new technology; securities issuance results already disclosed recently.
Alteogen shares plunge; Japanese media say company considering DDS introduction for growth
Predicted impact: Low· Actual: +2.2% vs sector, volume 1.0× normal (5 trading days)
Reports of DDS technology consideration repeat the same growth-strategy theme already covered.
Also known as: Alteogen / 알테오젠 / 196170 / KRX:196170
Source: KRX statistical information